SI3107559T1 - Režim odmerjanja spojine FGF-18 - Google Patents

Režim odmerjanja spojine FGF-18

Info

Publication number
SI3107559T1
SI3107559T1 SI201530428T SI201530428T SI3107559T1 SI 3107559 T1 SI3107559 T1 SI 3107559T1 SI 201530428 T SI201530428 T SI 201530428T SI 201530428 T SI201530428 T SI 201530428T SI 3107559 T1 SI3107559 T1 SI 3107559T1
Authority
SI
Slovenia
Prior art keywords
fgf
dosing regimen
compound dosing
compound
regimen
Prior art date
Application number
SI201530428T
Other languages
English (en)
Slovenian (sl)
Inventor
Christoph H. Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI3107559T1 publication Critical patent/SI3107559T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201530428T 2014-02-20 2015-02-20 Režim odmerjanja spojine FGF-18 SI3107559T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
EP15706006.2A EP3107559B1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
SI3107559T1 true SI3107559T1 (sl) 2018-11-30

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201530428T SI3107559T1 (sl) 2014-02-20 2015-02-20 Režim odmerjanja spojine FGF-18
SI201530410T SI3119417T1 (sl) 2014-02-20 2015-02-20 Režim odmerjanja spojine FGF-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201530410T SI3119417T1 (sl) 2014-02-20 2015-02-20 Režim odmerjanja spojine FGF-18

Country Status (25)

Country Link
US (2) US9889179B2 (Direct)
EP (2) EP3119417B1 (Direct)
JP (2) JP6431083B2 (Direct)
KR (2) KR102410986B1 (Direct)
CN (2) CN106232622A (Direct)
AR (2) AR099510A1 (Direct)
AU (2) AU2015220777B2 (Direct)
BR (2) BR112016018685A2 (Direct)
CA (2) CA2938791A1 (Direct)
DK (2) DK3107559T3 (Direct)
ES (2) ES2688551T3 (Direct)
HR (2) HRP20181570T1 (Direct)
HU (1) HUE040350T2 (Direct)
IL (2) IL247084B (Direct)
LT (2) LT3107559T (Direct)
MX (2) MX2016010872A (Direct)
NZ (1) NZ723148A (Direct)
PL (2) PL3107559T3 (Direct)
PT (2) PT3107559T (Direct)
RS (2) RS57853B1 (Direct)
RU (2) RU2691946C2 (Direct)
SG (2) SG11201606502YA (Direct)
SI (2) SI3107559T1 (Direct)
WO (2) WO2015124727A1 (Direct)
ZA (2) ZA201605547B (Direct)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
CA2938791A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 compound dosing regimen
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
HUE058786T2 (hu) 2017-09-29 2022-09-28 Merck Patent Gmbh FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek
DK3688468T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CA3127729A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
US20060009389A1 (en) * 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
KR101419961B1 (ko) * 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Fgf-18 로 연골 질환의 치료
CN101505787B (zh) * 2006-08-25 2013-09-04 阿雷斯贸易股份有限公司 软骨障碍的治疗
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
CA2830882C (en) * 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP3107591B1 (en) 2014-02-20 2018-04-18 Merck Patent GmbH Fgf-18 in graft transplantation and tissue engineering procedures
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
CA2938791A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 compound dosing regimen

Also Published As

Publication number Publication date
JP6431082B2 (ja) 2018-11-28
RU2016137292A (ru) 2018-03-21
CN106456713A (zh) 2017-02-22
US9889179B2 (en) 2018-02-13
CN106232622A (zh) 2016-12-14
WO2015124727A1 (en) 2015-08-27
LT3107559T (lt) 2018-10-25
ES2688551T3 (es) 2018-11-05
RS57709B1 (sr) 2018-12-31
NZ723139A (en) 2022-12-23
RU2016137292A3 (Direct) 2018-09-17
IL247083A0 (en) 2016-09-29
RU2016137289A3 (Direct) 2018-10-19
CA2938791A1 (en) 2015-08-27
AU2015220773A1 (en) 2016-09-01
RU2016137289A (ru) 2018-03-21
HRP20181572T1 (hr) 2018-11-30
HUE040350T2 (hu) 2019-03-28
IL247084B (en) 2019-09-26
IL247084A0 (en) 2016-09-29
BR112016018696A2 (pt) 2017-10-17
KR102410986B1 (ko) 2022-06-17
RU2700582C2 (ru) 2019-09-18
SI3119417T1 (sl) 2018-11-30
ZA201605547B (en) 2019-09-25
NZ723148A (en) 2022-08-26
RS57853B1 (sr) 2018-12-31
AU2015220777B2 (en) 2020-10-22
PL3107559T3 (pl) 2019-01-31
PT3119417T (pt) 2018-10-31
JP2017512194A (ja) 2017-05-18
RU2691946C2 (ru) 2019-06-19
PL3119417T3 (pl) 2019-01-31
WO2015124731A1 (en) 2015-08-27
MX2016010871A (es) 2016-11-17
US9724388B2 (en) 2017-08-08
MX2016010872A (es) 2016-11-17
AR099558A1 (es) 2016-08-03
CA2938793A1 (en) 2015-08-27
KR20160116001A (ko) 2016-10-06
HRP20181570T1 (hr) 2018-11-30
SG11201606502YA (en) 2016-09-29
US20170072017A1 (en) 2017-03-16
IL247083B (en) 2019-09-26
KR102410988B1 (ko) 2022-06-17
KR20160116000A (ko) 2016-10-06
ES2689071T3 (es) 2018-11-08
LT3119417T (lt) 2018-10-25
DK3119417T3 (en) 2018-10-22
AR099510A1 (es) 2016-07-27
BR112016018685A2 (pt) 2017-10-17
EP3107559B1 (en) 2018-07-11
EP3119417A1 (en) 2017-01-25
SG11201606505UA (en) 2016-09-29
EP3107559A1 (en) 2016-12-28
US20170056474A1 (en) 2017-03-02
JP2017507142A (ja) 2017-03-16
EP3119417B1 (en) 2018-07-11
JP6431083B2 (ja) 2018-11-28
DK3107559T3 (en) 2018-10-15
AU2015220773B2 (en) 2020-10-08
AU2015220777A1 (en) 2016-09-01
ZA201605548B (en) 2018-12-19
PT3107559T (pt) 2018-10-31

Similar Documents

Publication Publication Date Title
GB2544029B (en) Packages
GB201508180D0 (en) Antibodies
PT3347054T (pt) Regimes de dosagem para conjugados fármaco-anticorpo anti-tf
ZA201605547B (en) Fgf-18 compound dosing regimen
GB2545674B (en) Dosing module
GB201510451D0 (en) Actuated-valve metering
GB201509907D0 (en) Antibodies
GB201418710D0 (en) Dosage regimen
ZA201800217B (en) Novel dosage regimen tiacumicin compound
GB201516836D0 (en) Dosing regimen of combination
SI3139932T1 (sl) Režim zdravljenja za spojino tiacumicina
GB201503438D0 (en) Antibodies
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201609758D0 (en) Dosing Regimen
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201713609D0 (en) Packages
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies